RJFSA
KRYS icon

Raymond James Financial Services Advisors’s Krystal Biotech KRYS Stock Holding History

Raymond James Financial Services Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$245K Buy
1,348
+35
+3% +$6.75K ﹤0.01% 3057
2024
Q2 		$241K Hold
1,313
– – ﹤0.01% 3009
2024
Q1 		$234K Buy
+1,313
New +$182K ﹤0.01% 3004

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's KRYS Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Krystal Biotech (KRYS) stake by 2.7% in Q3 2024, buying an estimated $6.75K and bringing the position to 1,348 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #3057.

Raymond James Financial Services Advisors first reported a position in KRYS in Q1 2024 and has held it in 3 quarters since. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Raymond James Financial Services Advisors held 1,348 shares of Krystal Biotech worth $245K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 35 Krystal Biotech shares in Q3 2024, an estimated $6.75K.
  • Krystal Biotech made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3057 holding.
  • Raymond James Financial Services Advisors first reported a position in Krystal Biotech in Q1 2024 and has held it in 3 quarters since.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.